Genetic Signatures Limited (ASX:GSS)
Australia · Delayed Price · Currency is AUD | Market Cap | 18.40M -71.1% |
| Revenue (ttm) | 19.33M -2.1% |
| Net Income | -14.01M |
| EPS | -0.06 |
| Shares Out | 227.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,136 |
| Open | 0.0870 |
| Previous Close | 0.0810 |
| Day's Range | 0.0870 - 0.0870 |
| 52-Week Range | 0.0510 - 0.4300 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 25, 2026 |
About Genetic Signatures
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Aust... [Read more]
Financial Performance
In fiscal year 2026, Genetic Signatures's revenue was 19.33 million, a decrease of -2.14% compared to the previous year's 19.75 million. Losses were -14.01 million, -30.33% less than in 2025.
Financial StatementsNews
Genetic Signatures Earnings Call Transcript: H2 2026
FY 2026 saw a 7% revenue decline to AUD 14.8 million, but net loss narrowed by 30% and cash outflow dropped significantly. Cost savings from restructuring and new long-term contracts support a stable outlook, with APAC and EMEA targeted for future growth.
Genetic Signatures Annual report: H2 2026
Genetic Signatures has published its H2 2026 annual report on August 25, 2026.
Genetic Signatures Earnings release: H2 2026
Genetic Signatures released its H2 2026 earnings on August 25, 2026, summarizing the period's financial results.
Genetic Signatures Slides: H2 2026
Genetic Signatures has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 25, 2026.
Genetic Signatures Transcript: Investor update
A comprehensive restructuring delivered AUD 5 million in annualized cost savings and reset leadership, while product upgrades and new supply agreements strengthened positions in EMEA and Australia. U.S. market entry and major instrument projects are paused pending strategic review.
Genetic Signatures Slides: Investor update
Genetic Signatures has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Genetic Signatures Earnings release: Q3 2026
Genetic Signatures released its Q3 2026 earnings on April 28, 2026, summarizing the period's financial results.
Genetic Signatures Earnings Call Transcript: H1 2026
Revenue rose slightly to AUD 8.7 million, but gross margin declined due to higher costs. U.S. expansion remains a focus, with new customers and product development underway, while a forensic review targets cost reductions to address high cash burn.
Genetic Signatures Quarterly report: H1 2026
Genetic Signatures has published its H1 2026 quarterly earnings report on February 25, 2026.
Genetic Signatures Slides: H1 2026
Genetic Signatures has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 25, 2026.
Genetic Signatures Earnings release: H1 2026
Genetic Signatures released its H1 2026 earnings on February 25, 2026, summarizing the period's financial results.
Genetic Signatures Slides: FY 2025
Genetic Signatures has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 16, 2025.
Genetic Signatures Earnings release: Q1 2026
Genetic Signatures released its Q1 2026 earnings on October 20, 2025, summarizing the period's financial results.